HC Wainwright Reaffirms "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

HC Wainwright reiterated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $36.00 target price on the stock.

A number of other equities analysts have also issued reports on the stock. Leerink Partners reiterated an "outperform" rating and set a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Chardan Capital reissued a "buy" rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Royal Bank of Canada cut their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a research note on Thursday, November 14th. Morgan Stanley began coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an "underweight" rating and a $8.00 target price on the stock. Finally, Bank of America dropped their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $38.56.

4D Molecular Therapeutics Trading Down 13.8 %

Shares of 4D Molecular Therapeutics stock traded down $0.76 during trading on Monday, reaching $4.76. The company's stock had a trading volume of 1,369,122 shares, compared to its average volume of 828,889. The stock has a 50-day moving average price of $6.94 and a two-hundred day moving average price of $11.88. The stock has a market capitalization of $220.05 million, a P/E ratio of -1.67 and a beta of 2.81. 4D Molecular Therapeutics has a one year low of $4.68 and a one year high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $40,000. Values First Advisors Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the third quarter worth $57,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock worth $108,000 after buying an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at about $108,000. Finally, Quest Partners LLC grew its stake in shares of 4D Molecular Therapeutics by 17,409.1% in the second quarter. Quest Partners LLC now owns 5,778 shares of the company's stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.